BAKER BROS. ADVISORS LP Q1 2017 Filing
Filed May 15, 2017
Portfolio Value
$12.2B
Holdings
119
Report Date
Q1 2017
Filing Type
13F-HR
All Holdings (119 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | INCYIncyte Corporation | 34,110,011 | $4.6T | 37309.55% | |
| 2 | SGENEURSeattle Genetics, Inc. | 45,715,556 | $2.9T | 23514.87% | |
| 3 | ACADACADIA Pharmaceuticals Inc. | 25,819,768 | $887.7B | 7263.78% | |
| 4 | ALXNAlexion Pharmaceuticals, Inc. | 6,544,130 | $793.4B | 6492.35% | |
| 5 | —Genomic Health, Inc. | 13,770,982 | $433.6B | 3548.47% | |
| 6 | BMRNBioMarin Pharmaceutical Inc. | 4,806,483 | $421.9B | 3452.45% | |
| 7 | —DBV Technologies S.A. | 5,509,560 | $194.0B | 1587.86% | |
| 8 | —Aquinox Pharmaceuticals, Inc. | 10,934,154 | $182.5B | 1493.30% | |
| 9 | ONCBeiGene, Ltd. | 3,673,175 | $134.5B | 1100.39% | |
| 10 | —Achaogen, Inc. | 4,582,382 | $115.6B | 946.04% | |
| 11 | BCRXBioCryst Pharmaceuticals, Inc. | 11,716,784 | $98.4B | 805.36% | |
| 12 | —BioMarin Pharmaceutical Inc. | 22,379,000 | $96.0B | 785.28% | |
| 13 | —Advanced Accelerator Applications S.A. | 2,221,706 | $88.6B | 724.65% | |
| 14 | NVTA1EURInvitae Corporation | 7,288,300 | $80.6B | 659.61% | |
| 15 | AMRNAmarin Corporation plc | 22,656,469 | $72.5B | 593.26% | |
| 16 | —Spark Therapeutics, Inc. | 1,318,341 | $70.3B | 575.42% | |
| 17 | —Acorda Therapeutics, Inc. | 3,301,791 | $69.3B | 567.38% | |
| 18 | —Bellicum Pharmaceuticals, Inc. | 5,032,313 | $62.1B | 508.15% | |
| 19 | CERSCerus Corporation | 13,053,275 | $58.1B | 475.32% | |
| 20 | EX9Exelixis, Inc. | 2,603,569 | $56.4B | 461.67% | |
| 21 | NVAX 3.75 02/01/23Novavax, Inc. | 108,500,000 | $48.6B | 397.31% | |
| 22 | HRTXHeron Therapeutics, Inc. | 2,783,569 | $41.8B | 341.67% | |
| 23 | NBIXNeurocrine Biosciences, Inc. | 895,422 | $38.8B | 317.27% | |
| 24 | —AveXis, Inc. | 500,000 | $38.0B | 311.07% | |
| 25 | ASNDAscendis Pharma A/S | 1,351,463 | $37.8B | 309.65% | |
| 26 | —Versartis, Inc. | 1,660,593 | $35.5B | 290.11% | |
| 27 | —bluebird bio, Inc. | 351,441 | $31.9B | 261.41% | |
| 28 | —Progenics Pharmaceuticals, Inc. | 3,150,808 | $29.7B | 243.39% | |
| 29 | —Acorda Therapeutics, Inc. | 35,083,000 | $29.7B | 243.00% | |
| 30 | MRUSMerus N.V. | 1,160,014 | $28.3B | 231.52% | |
| 31 | —Idera Pharmaceuticals, Inc. | 10,286,483 | $25.4B | 207.91% | |
| 32 | GBYSangamo Therapeutics, Inc. | 4,530,901 | $23.6B | 192.80% | |
| 33 | GLPGGalapagos NV | 259,894 | $22.4B | 183.30% | |
| 34 | XNCRXencor, Inc. | 872,072 | $20.9B | 170.69% | |
| 35 | HALOHalozyme Therapeutics, Inc. | 1,391,507 | $18.0B | 147.57% | |
| 36 | —NeuroDerm Ltd. | 571,667 | $15.2B | 124.20% | |
| 37 | NTLAIntellia Therapeutics, Inc. | 1,062,120 | $15.0B | 122.46% | |
| 38 | SG7Sage Therapeutics, Inc. | 208,328 | $14.8B | 121.16% | |
| 39 | —Aimmune Therapeutics, Inc. | 673,908 | $14.6B | 119.83% | |
| 40 | ARRYEURArray BioPharma Inc. | 1,585,913 | $14.2B | 116.02% | |
| 41 | —Dermira, Inc. | 415,448 | $14.2B | 115.96% | |
| 42 | —BioMarin Pharmaceutical Inc. | 12,228,000 | $13.8B | 113.17% | |
| 43 | AERIEURAerie Pharmaceuticals, Inc. | 299,356 | $13.6B | 111.09% | |
| 44 | —Aegerion Pharmaceuticals, Inc. | 16,517,000 | $13.2B | 108.35% | |
| 45 | —Foamix Pharmaceuticals Ltd. | 2,466,702 | $12.2B | 99.91% | |
| 46 | MRTXEURMirati Therapeutics, Inc. | 2,269,198 | $11.8B | 96.56% | |
| 47 | IMGNEURImmunoGen, Inc. | 3,015,353 | $11.7B | 95.49% | |
| 48 | —La Jolla Pharmaceutical Company | 379,134 | $11.3B | 92.61% | |
| 49 | CPRXCatalyst Pharmaceuticals, Inc. | 5,102,153 | $9.9B | 81.41% | |
| 50 | ITCIEURIntra-Cellular Therapies, Inc. | 609,166 | $9.9B | 81.00% | |
| 51 | ALKSAlkermes plc | 150,251 | $8.8B | 71.93% | |
| 52 | —Abeona Therapeutics Inc. | 1,684,364 | $8.4B | 68.92% | |
| 53 | RIGLUSDRigel Pharmaceuticals, Inc. | 2,518,882 | $8.3B | 68.22% | |
| 54 | —Achillion Pharmaceuticals, Inc. | 1,856,637 | $7.8B | 63.96% | |
| 55 | LGNDLigand Pharmaceuticals Incorporated | 73,386 | $7.8B | 63.56% | |
| 56 | AGIOAgios Pharmaceuticals, Inc. | 128,666 | $7.5B | 61.49% | |
| 57 | —ContraFect Corporation | 4,045,876 | $7.3B | 59.60% | |
| 58 | IM8NInsmed Incorporated | 400,000 | $7.0B | 57.31% | |
| 59 | MGNXMacroGenics, Inc. | 363,676 | $6.8B | 55.35% | |
| 60 | ASMBAssembly Biosciences, Inc. | 250,000 | $6.4B | 52.15% | |
| 61 | CBAYUSDCymaBay Therapeutics, Inc. | 1,413,499 | $6.1B | 49.74% | |
| 62 | —Loxo Oncology, Inc. | 137,735 | $5.8B | 47.43% | |
| 63 | —Akari Therapeutics plc | 496,901 | $5.5B | 45.01% | |
| 64 | —Stemline Therapeutics, Inc. | 633,497 | $5.4B | 44.32% | |
| 65 | —Ignyta, Inc. | 571,000 | $4.9B | 40.19% | |
| 66 | —Alder BioPharmaceuticals, Inc. | 217,328 | $4.5B | 36.99% | |
| 67 | BIIBBiogen Inc. | 16,500 | $4.5B | 36.91% | |
| 68 | —Array BioPharma Inc. | 3,000,000 | $4.3B | 34.84% | |
| 69 | —Nabriva Therapeutics AG | 350,000 | $4.2B | 34.37% | |
| 70 | ANABAnaptysBio, Inc. | 150,000 | $4.2B | 34.07% | |
| 71 | —Zogenix, Inc. | 381,939 | $4.1B | 33.91% | |
| 72 | —Epizyme, Inc. | 232,481 | $4.0B | 32.62% | |
| 73 | —Ra Pharmaceuticals, Inc. | 177,952 | $3.8B | 31.00% | |
| 74 | RAREUltragenyx Pharmaceutical Inc. | 50,000 | $3.4B | 27.73% | |
| 75 | —Syros Pharmaceuticals, Inc. | 204,465 | $3.3B | 26.65% | |
| 76 | —Trevena, Inc. | 857,206 | $3.1B | 25.74% | |
| 77 | —Sunesis Pharmaceuticals, Inc. | 741,665 | $3.0B | 24.88% | |
| 78 | —Adamas Pharmaceuticals, Inc. | 172,630 | $3.0B | 24.72% | |
| 79 | —Aevi Genomic Medicine, Inc. | 1,618,089 | $3.0B | 24.63% | |
| 80 | —Inotek Pharmaceuticals Corporation | 5,000,000 | $3.0B | 24.61% | |
| 81 | KPTIEURKaryopharm Therapeutics Inc. | 216,990 | $2.8B | 22.80% | |
| 82 | TREURTrillium Therapeutics Inc. | 413,697 | $2.5B | 20.82% | |
| 83 | —Protalix BioTherapeutics, Inc. | 3,423,000 | $2.5B | 20.81% | |
| 84 | SELBUSDSelecta Biosciences, Inc. | 175,712 | $2.5B | 20.59% | |
| 85 | JNCEEURJounce Therapeutics, Inc. | 100,000 | $2.2B | 17.99% | |
| 86 | —Dimension Therapeutics, Inc. | 1,251,881 | $2.2B | 17.93% | |
| 87 | —Tonix Pharmaceuticals Holdings Corp. | 449,500 | $2.1B | 17.18% | |
| 88 | GLYCEURGlycoMimetics, Inc. | 381,235 | $2.1B | 16.94% | |
| 89 | NTRANatera, Inc. | 228,676 | $2.0B | 16.59% | |
| 90 | —Spring Bank Pharmaceuticals, Inc. | 219,298 | $2.0B | 15.97% | |
| 91 | INFIQInfinity Pharmaceuticals, Inc. | 580,400 | $1.9B | 15.34% | |
| 92 | —InVivo Therapeutics Holdings Corp. | 400,000 | $1.6B | 13.26% | |
| 93 | —MediWound Ltd. | 226,000 | $1.5B | 12.21% | |
| 94 | AGLEUSDAeglea BioTherapeutics, Inc. | 189,987 | $1.4B | 11.58% | |
| 95 | MCRB1EURSeres Therapeutics, Inc. | 125,000 | $1.4B | 11.53% | |
| 96 | FLGTFulgent Genetics, Inc. | 125,000 | $1.4B | 11.17% | |
| 97 | —MyoKardia, Inc. | 100,000 | $1.3B | 10.76% | |
| 98 | CLLSCellectis S.A. | 50,000 | $1.2B | 9.82% | |
| 99 | —Juno Therapeutics, Inc. | 50,000 | $1.1B | 9.08% | |
| 100 | CRBPEURCorbus Pharmaceuticals Holdings, Inc. | 130,129 | $1.1B | 8.79% |
Page 1 of 2Next